查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1721220

核酸治療市場－全球產業分析、規模、佔有率、成長、趨勢及預測（2025-2035）

Nucleic Acid Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
出版日期: | 出版商: Transparency Market Research | 英文 213 Pages | 商品交期: 2-10個工作天內

價格

核酸治療市場 - 報告範圍

TMR 關於全球核酸治療市場的報告研究了過去和當前的成長趨勢和機會，以獲得 2025 年至 2035 年預測期內市場指標的寶貴見解。該報告提供了 2019 年至 2035 年期間全球核酸治療市場的收入，以 2025 年為基準年，2035 年為預測年。報告也提供了2025年至2035年全球核酸治療市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初步研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了訪談。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解核酸治療市場。

市場概況
2024 年的市場價值 88億美元
2035年的市場價值 445億美元
複合年成長率 14.7%

該報告深入探討了全球核酸治療市場的競爭格局。我們已經確定了在全球核酸治療市場中運作的關鍵參與者，並根據各種屬性對每位參與者進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告介紹的全球核酸治療市場參與者的屬性。

目錄

第1章：前言

第2章：假設與研究方法

第3章：執行摘要：全球市場

第4章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2020 - 2035 年全球核酸治療市場分析與預測

第5章：關鍵見解

  • 主要地區/國家的醫療保健支出
  • 核酸治療產業的技術進步
  • FDA核准清單
  • 核酸治療藥物定價趨勢
  • 核酸治療：臨床試驗分析
  • 資金和投資分析
  • 波特五力分析
  • 主要地區/國家的監管格局
  • 新市場進入者的市場進入策略
  • 最終用戶的關鍵購買指標
  • 重要產業事件（合作夥伴關係、協作、產品核准、併購）
  • 對主要競爭對手提供的產品基準化分析
  • 核酸治療的臨床前流程分析

第6章：全球市場分析與預測：依治療類型

  • 介紹與定義
  • 主要發現/進展
  • 市場價值預測：依治療類型，2020 - 2035
    • 反義寡核苷酸（ASO）
    • 小干擾RNA（siRNA）
    • 基因療法
    • 適體
    • 其他
  • 市場吸引力分析：按治療類型

第7章：全球市場分析與預測：以交付方式

  • 介紹與定義
  • 主要發現/進展
  • 市場價值預測：以交付方式，2020 - 2035
    • 基於病毒載體的遞送系統
    • 非病毒遞送系統
  • 市場吸引力分析：按交付方式

第8章：全球市場分析與預測：依管理途徑

  • 介紹與定義
  • 主要發現/進展
  • 市場價值預測：依給藥途徑，2020 - 2035
    • 靜脈
    • 皮下
    • 其他
  • 市場吸引力分析：按給藥途徑

第9章：全球市場分析及預測：依治療領域

  • 介紹和定義
  • 主要發現/進展
  • 市場價值預測：按治療領域，2020 - 2035
    • 神經肌肉疾病
    • 代謝紊亂
    • 心血管疾病
    • 眼科疾病
    • 腫瘤疾病
    • 其他
  • 市場吸引力分析：按治療領域

第10章：全球市場分析與預測：依最終用戶

  • 介紹和定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2020 - 2035
    • 醫院
    • 學術和研究機構
    • 其他
  • 市場吸引力分析：按最終用戶

第 11 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2020 - 2035
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第12章：北美市場分析與預測

第13章：歐洲市場分析與預測

第14章：亞太市場分析與預測

第15章：拉丁美洲市場分析與預測

第16章：中東與非洲市場分析與預測

第 17 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：按公司（2024年）
  • 公司簡介
    • Novartis AG
    • Pfizer, Inc.
    • Sanofi
    • Novo Nordisk A/S
    • AstraZeneca plc
    • Alnylam Pharmaceuticals, Inc.
    • Amgen Inc
    • Sarepta Therapeutics, Inc.
    • Bluebird Bio, Inc
    • CSL Behring LLC
    • Ferring Pharmaceuticals Inc.
    • Krystal Biotech, Inc.
    • PTC Therapeutics, Inc.
    • Jazz Pharmaceuticals plc
    • Astellas Pharma Inc.
Product Code: TMRGL86333

Nucleic Acid Therapeutics Market - Scope of Report

TMR's report on the global nucleic acid therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global nucleic acid therapeutics market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nucleic acid therapeutics market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the nucleic acid therapeutics market.

Market Snapshot
Market Value in 2024US$ 8.8 Bn
Market Value in 2035US$ 44.5 Bn
CAGR14.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nucleic acid therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nucleic acid therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nucleic acid therapeutics market.

The report delves into the competitive landscape of the global nucleic acid therapeutics market. Key players operating in the global nucleic acid therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nucleic acid therapeutics market profiled in this report.

Key Questions Answered in Global nucleic acid therapeutics market Report:

  • What is the sales/revenue generated by nucleic acid therapeutics across all regions during the forecast period?
  • What are the opportunities in the global nucleic acid therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Nucleic Acid Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global nucleic acid therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nucleic acid therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nucleic acid therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nucleic Acid Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecast, 2020 - 2035
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Healthcare Expenditure across Key Regions / Countries
  • 5.2. Technological Advancements in Nucleic Acid Therapeutics Industry
  • 5.3. List of Nucleic Acid Therapeutics Approved by FDA
  • 5.4. Nucleic Acid Therapeutics Pricing Trends
  • 5.5. Nucleic Acid Therapeutics: Clinical Trial Analysis
  • 5.6. Funding and Investments Analysis
  • 5.7. PORTER's Five Forces Analysis
  • 5.8. Regulatory Landscape across Key Regions / Countries
  • 5.9. Go-to-Market Strategy for New Market Entrants
  • 5.10. Key Purchase Metrics for End-users
  • 5.11. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)
  • 5.12. Benchmarking of the Products Offered by the Leading Competitors
  • 5.13. Preclinical Pipeline Analysis for Nucleic Acid Therapeutics

6. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Therapy Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 6.3.1. Antisense oligonucleotides (ASOs)
    • 6.3.2. Small interfering R(siRNA)
    • 6.3.3. Gene Therapies
    • 6.3.4. Aptamers
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Therapy Type

7. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Delivery Method

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 7.3.1. Viral vector-based Delivery Systems
    • 7.3.2. Non-viral Delivery Systems
  • 7.4. Market Attractiveness Analysis, by Delivery Method

8. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 8.3.1. Intravenous
    • 8.3.2. Subcutaneous
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Therapeutic Area

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 9.3.1. Neuromuscular Disorder
    • 9.3.2. Metabolic Disorders
    • 9.3.3. Cardiovascular Disorders
    • 9.3.4. Ophthalmological Disorders
    • 9.3.5. Oncological Disorders
    • 9.3.6. Others
  • 9.4. Market Attractiveness Analysis, by Therapeutic Area

10. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by End-user

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by End-user, 2020 - 2035
    • 10.3.1. Hospitals
    • 10.3.2. Academic and Research Institutes
    • 10.3.3. Others
  • 10.4. Market Attractiveness Analysis, by End-user

11. Global Nucleic Acid Therapeutics Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2020 - 2035
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Nucleic Acid Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 12.2.1. Antisense oligonucleotides (ASOs)
    • 12.2.2. Small interfering R(siRNA)
    • 12.2.3. Gene Therapies
    • 12.2.4. Aptamers
    • 12.2.5. Others
  • 12.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 12.3.1. Viral vector-based Delivery Systems
    • 12.3.2. Non-viral Delivery Systems
  • 12.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 12.4.1. Intravenous
    • 12.4.2. Subcutaneous
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 12.5.1. Neuromuscular Disorder
    • 12.5.2. Metabolic Disorders
    • 12.5.3. Cardiovascular Disorders
    • 12.5.4. Ophthalmological Disorders
    • 12.5.5. Oncological Disorders
    • 12.5.6. Others
  • 12.6. Market Value Forecast, by End-user, 2020 - 2035
    • 12.6.1. Hospitals
    • 12.6.2. Academic and Research Institutes
    • 12.6.3. Others
  • 12.7. Market Value Forecast, by Country, 2020 - 2035
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Therapy Type
    • 12.8.2. By Delivery Method
    • 12.8.3. By Route of Administration
    • 12.8.4. By Therapeutic Area
    • 12.8.5. By End-user
    • 12.8.6. By Country

13. Europe Nucleic Acid Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 13.2.1. Antisense oligonucleotides (ASOs)
    • 13.2.2. Small interfering R(siRNA)
    • 13.2.3. Gene Therapies
    • 13.2.4. Aptamers
    • 13.2.5. Others
  • 13.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 13.3.1. Viral vector-based Delivery Systems
    • 13.3.2. Non-viral Delivery Systems
  • 13.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 13.4.1. Intravenous
    • 13.4.2. Subcutaneous
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 13.5.1. Neuromuscular Disorder
    • 13.5.2. Metabolic Disorders
    • 13.5.3. Cardiovascular Disorders
    • 13.5.4. Ophthalmological Disorders
    • 13.5.5. Oncological Disorders
    • 13.5.6. Others
  • 13.6. Market Value Forecast, by End-user, 2020 - 2035
    • 13.6.1. Hospitals
    • 13.6.2. Academic and Research Institutes
    • 13.6.3. Others
  • 13.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
    • 13.7.1. Germany
    • 13.7.2. UK
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Therapy Type
    • 13.8.2. By Delivery Method
    • 13.8.3. By Route of Administration
    • 13.8.4. By Therapeutic Area
    • 13.8.5. By End-user
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 14.2.1. Antisense oligonucleotides (ASOs)
    • 14.2.2. Small interfering R(siRNA)
    • 14.2.3. Gene Therapies
    • 14.2.4. Aptamers
    • 14.2.5. Others
  • 14.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 14.3.1. Viral vector-based Delivery Systems
    • 14.3.2. Non-viral Delivery Systems
  • 14.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 14.4.1. Intravenous
    • 14.4.2. Subcutaneous
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 14.5.1. Neuromuscular Disorder
    • 14.5.2. Metabolic Disorders
    • 14.5.3. Cardiovascular Disorders
    • 14.5.4. Ophthalmological Disorders
    • 14.5.5. Oncological Disorders
    • 14.5.6. Others
  • 14.6. Market Value Forecast, by End-user, 2020 - 2035
    • 14.6.1. Hospitals
    • 14.6.2. Academic and Research Institutes
    • 14.6.3. Others
  • 14.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Therapy Type
    • 14.8.2. By Delivery Method
    • 14.8.3. By Route of Administration
    • 14.8.4. By Therapeutic Area
    • 14.8.5. By End-user
    • 14.8.6. By Country/Sub-region

15. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 15.2.1. Antisense oligonucleotides (ASOs)
    • 15.2.2. Small interfering R(siRNA)
    • 15.2.3. Gene Therapies
    • 15.2.4. Aptamers
    • 15.2.5. Others
  • 15.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 15.3.1. Viral vector-based Delivery Systems
    • 15.3.2. Non-viral Delivery Systems
  • 15.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 15.4.1. Intravenous
    • 15.4.2. Subcutaneous
    • 15.4.3. Others
  • 15.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 15.5.1. Neuromuscular Disorder
    • 15.5.2. Metabolic Disorders
    • 15.5.3. Cardiovascular Disorders
    • 15.5.4. Ophthalmological Disorders
    • 15.5.5. Oncological Disorders
    • 15.5.6. Others
  • 15.6. Market Value Forecast, by End-user, 2020 - 2035
    • 15.6.1. Hospitals
    • 15.6.2. Academic and Research Institutes
    • 15.6.3. Others
  • 15.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Therapy Type
    • 15.8.2. By Delivery Method
    • 15.8.3. By Route of Administration
    • 15.8.4. By Therapeutic Area
    • 15.8.5. By End-user
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Therapy Type, 2020 - 2035
    • 16.2.1. Antisense oligonucleotides (ASOs)
    • 16.2.2. Small interfering R(siRNA)
    • 16.2.3. Gene Therapies
    • 16.2.4. Aptamers
    • 16.2.5. Others
  • 16.3. Market Value Forecast, by Delivery Method, 2020 - 2035
    • 16.3.1. Viral vector-based Delivery Systems
    • 16.3.2. Non-viral Delivery Systems
  • 16.4. Market Value Forecast, by Route of Administration, 2020 - 2035
    • 16.4.1. Intravenous
    • 16.4.2. Subcutaneous
    • 16.4.3. Others
  • 16.5. Market Value Forecast, by Therapeutic Area, 2020 - 2035
    • 16.5.1. Neuromuscular Disorder
    • 16.5.2. Metabolic Disorders
    • 16.5.3. Cardiovascular Disorders
    • 16.5.4. Ophthalmological Disorders
    • 16.5.5. Oncological Disorders
    • 16.5.6. Others
  • 16.6. Market Value Forecast, by End-user, 2020 - 2035
    • 16.6.1. Hospitals
    • 16.6.2. Academic and Research Institutes
    • 16.6.3. Others
  • 16.7. Market Value Forecast, by Country/Sub-region, 2020 - 2035
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Therapy Type
    • 16.8.2. By Delivery Method
    • 16.8.3. By Route of Administration
    • 16.8.4. By Therapeutic Area
    • 16.8.5. By End-user
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 17.2. Market Share Analysis, by Company (2024)
  • 17.3. Company Profiles
    • 17.3.1. Novartis AG
      • 17.3.1.1. Company Overview
      • 17.3.1.2. Financial Overview
      • 17.3.1.3. Product Portfolio
      • 17.3.1.4. Business Strategies
      • 17.3.1.5. Recent Developments
    • 17.3.2. Pfizer, Inc.
      • 17.3.2.1. Company Overview
      • 17.3.2.2. Financial Overview
      • 17.3.2.3. Product Portfolio
      • 17.3.2.4. Business Strategies
      • 17.3.2.5. Recent Developments
    • 17.3.3. Sanofi
      • 17.3.3.1. Company Overview
      • 17.3.3.2. Financial Overview
      • 17.3.3.3. Product Portfolio
      • 17.3.3.4. Business Strategies
      • 17.3.3.5. Recent Developments
    • 17.3.4. Novo Nordisk A/S
      • 17.3.4.1. Company Overview
      • 17.3.4.2. Financial Overview
      • 17.3.4.3. Product Portfolio
      • 17.3.4.4. Business Strategies
      • 17.3.4.5. Recent Developments
    • 17.3.5. AstraZeneca plc
      • 17.3.5.1. Company Overview
      • 17.3.5.2. Financial Overview
      • 17.3.5.3. Product Portfolio
      • 17.3.5.4. Business Strategies
      • 17.3.5.5. Recent Developments
    • 17.3.6. Alnylam Pharmaceuticals, Inc.
      • 17.3.6.1. Company Overview
      • 17.3.6.2. Financial Overview
      • 17.3.6.3. Product Portfolio
      • 17.3.6.4. Business Strategies
      • 17.3.6.5. Recent Developments
    • 17.3.7. Amgen Inc
      • 17.3.7.1. Company Overview
      • 17.3.7.2. Financial Overview
      • 17.3.7.3. Product Portfolio
      • 17.3.7.4. Business Strategies
      • 17.3.7.5. Recent Developments
    • 17.3.8. Sarepta Therapeutics, Inc.
      • 17.3.8.1. Company Overview
      • 17.3.8.2. Financial Overview
      • 17.3.8.3. Product Portfolio
      • 17.3.8.4. Business Strategies
      • 17.3.8.5. Recent Developments
    • 17.3.9. Bluebird Bio, Inc
      • 17.3.9.1. Company Overview
      • 17.3.9.2. Financial Overview
      • 17.3.9.3. Product Portfolio
      • 17.3.9.4. Business Strategies
      • 17.3.9.5. Recent Developments
    • 17.3.10. CSL Behring LLC
      • 17.3.10.1. Company Overview
      • 17.3.10.2. Financial Overview
      • 17.3.10.3. Product Portfolio
      • 17.3.10.4. Business Strategies
      • 17.3.10.5. Recent Developments
    • 17.3.11. Ferring Pharmaceuticals Inc.
      • 17.3.11.1. Company Overview
      • 17.3.11.2. Financial Overview
      • 17.3.11.3. Product Portfolio
      • 17.3.11.4. Business Strategies
      • 17.3.11.5. Recent Developments
    • 17.3.12. Krystal Biotech, Inc.
      • 17.3.12.1. Company Overview
      • 17.3.12.2. Financial Overview
      • 17.3.12.3. Product Portfolio
      • 17.3.12.4. Business Strategies
      • 17.3.12.5. Recent Developments
    • 17.3.13. PTC Therapeutics, Inc.
      • 17.3.13.1. Company Overview
      • 17.3.13.2. Financial Overview
      • 17.3.13.3. Product Portfolio
      • 17.3.13.4. Business Strategies
      • 17.3.13.5. Recent Developments
    • 17.3.14. Jazz Pharmaceuticals plc
      • 17.3.14.1. Company Overview
      • 17.3.14.2. Financial Overview
      • 17.3.14.3. Product Portfolio
      • 17.3.14.4. Business Strategies
      • 17.3.14.5. Recent Developments
    • 17.3.15. Astellas Pharma Inc.
      • 17.3.15.1. Company Overview
      • 17.3.15.2. Financial Overview
      • 17.3.15.3. Product Portfolio
      • 17.3.15.4. Business Strategies
      • 17.3.15.5. Recent Developments

List of Tables

  • Table 01: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 02: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 03: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 04: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 05: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 06: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Region, 2020 - 2035
  • Table 07: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 08: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 09: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 10: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 11: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 12: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 13: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 14: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 15: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 16: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 17: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 18: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 19: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 20: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 21: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 22: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 23: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 24: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 25: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 26: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 27: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 28: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 29: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 30: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035
  • Table 31: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 32: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapy Type, 2020 - 2035
  • Table 33: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Delivery Method, 2020 - 2035
  • Table 34: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020 - 2035
  • Table 35: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 - 2035
  • Table 36: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, By End-user, 2020 - 2035

List of Figures

  • Figure 01: Global Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 02: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 03: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 04: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Antisense oligonucleotides (ASOs), 2020 - 2035
  • Figure 05: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Small interfering RNA (siRNA), 2020 - 2035
  • Figure 06: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Gene Therapies, 2020 - 2035
  • Figure 07: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Aptamers, 2020 - 2035
  • Figure 08: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
  • Figure 09: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 10: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 11: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Viral vector-based Delivery Systems, 2020 - 2035
  • Figure 12: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Non-viral Delivery Systems, 2020 - 2035
  • Figure 13: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 14: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 15: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Intravenous, 2020 - 2035
  • Figure 16: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Subcutaneous, 2020 - 2035
  • Figure 17: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
  • Figure 18: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 19: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 20: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Neuromuscular Disorder, 2020 - 2035
  • Figure 21: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Metabolic Disorders, 2020 - 2035
  • Figure 22: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Cardiovascular Disorders, 2020 - 2035
  • Figure 23: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Ophthalmological Disorders, 2020 - 2035
  • Figure 24: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Oncological Disorders, 2020 - 2035
  • Figure 25: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
  • Figure 26: Global Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 27: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 28: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Hospitals, 2020 - 2035
  • Figure 29: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Academic and Research Institutes, 2020 - 2035
  • Figure 30: Global Nucleic Acid Therapeutics Market Revenue (US$ Mn), by Others, 2020 - 2035
  • Figure 31: Global Nucleic Acid Therapeutics Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 32: Global Nucleic Acid Therapeutics Market Attractiveness Analysis, By Region, 2025 - 2035
  • Figure 33: North America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 34: North America Nucleic Acid Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 35: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country, 2025 - 2035
  • Figure 36: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 37: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 38: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 39: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 40: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 41: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 42: North America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 43: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 44: North America Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 45: North America Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 46: Europe Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 47: Europe Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 48: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
  • Figure 49: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 50: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 51: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 52: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 53: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 54: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 55: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 56: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 57: Europe Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 58: Europe Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 59: Asia Pacific Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 60: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 61: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2025 - 2035
  • Figure 62: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 63: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 64: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 65: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 66: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 67: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 68: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 69: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 70: Asia Pacific Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 71: Asia Pacific Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 72: Latin America Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 73: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 74: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
  • Figure 75: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 76: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 77: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 78: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 79: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 80: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 81: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 82: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 83: Latin America Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 84: Latin America Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035
  • Figure 85: Middle East & Africa Nucleic Acid Therapeutics Market Value (US$ Mn) Forecast, 2020 - 2035
  • Figure 86: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 87: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025 - 2035
  • Figure 88: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Therapy Type, 2024 and 2035
  • Figure 89: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapy Type, 2025 - 2035
  • Figure 90: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Delivery Method, 2024 and 2035
  • Figure 91: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Delivery Method, 2025 - 2035
  • Figure 92: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 93: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025 - 2035
  • Figure 94: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 95: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By Therapeutic Area, 2025 - 2035
  • Figure 96: Middle East & Africa Nucleic Acid Therapeutics Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 97: Middle East & Africa Nucleic Acid Therapeutics Market Attractiveness Analysis, By End-user, 2025 - 2035